Lung Cancer (Non-Small Cell)NCT07214441
Evaluating the Feasibility and Preliminary Effects of BE+
A study testing Breathe Easier+ in people with Lung Cancer (Non-Small Cell) and Self-management Behavior, run by University of South Carolina at 1 site in United States.
Trial summary
This non-randomized, single group study will test a 12-week, behavioral intervention for physical activity and stress management for survivors of non-small cell lung cancer (NSCLC) and a partner (family member or friend). Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Lung Cancer (Non-Small Cell), Self-management Behavior, Physical Activity
- What is being tested?
- Breathe Easier+
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Aug 2025to May 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Survivors of NSCLC who have completed definitive treatment within the last 2 years.
- All participants must have a health clearance for physical activity signed by a healthcare provider; have Wi-Fi access; be able to provide informed consent; and be able to speak and read English.
Who cannot join
- Survivors on current definitive treatment.
- All participants with a history of recurrent falls; a substantial mobility impairment related to chronic disease or injury; and lack of physical activity readiness as determined by a healthcare provider.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of South Carolina
Columbia, South Carolina, 29208
About this study
Official title: Evaluating the Feasibility and Preliminary Effects of a Remotely Delivered Dyad-Based Intervention Incorporating Resistance Training to Improve Fitness in Individuals With Non-Small-Cell Lung Cancer and in Their Partners
This non-randomized, single group study will test a 12-week, behavioral intervention for physical activity and stress management for survivors of non-small cell lung cancer (NSCLC) and a partner (family member or friend). The goals of this intervention, Breathe Easier+ (BE+), are to increase overall physical activity and overall fitness and to reduce symptoms (fatigue, breathlessness, sleep, and stress).
The aim of this study is to evaluate the enrollment, retention, adherence, participation, and acceptability of the 12-week BE+ among NSCLC survivors and their partners. The study also aims to:
Read more
- Explore preliminary intervention effects of BE+ on increasing physical activity and overall fitness (measured by 7-day Fitbit wear, step-in-place test, chair sit-and-stand, arm curl test, and balance test) from baseline to post-intervention among NSCLC survivors and their partners.
- Explore preliminary effects of BE+ for improvement in stress response, symptom burden (fatigue, dyspnea), sleep, and HRQL from baseline to post-intervention among NSCLC survivors and their partners.
Participants will receive education, social support, coaching, a guided walking program, supervised resistance training (RT), and meditations delivered via digital technology (tablet, smartphone, and Fitbit).
Read the detailed description
Lung cancer is the second-most diagnosed malignancy, accounting for more annual deaths than breast, prostate, and colorectal cancers combined. Approximately 80% of lung cancer diagnoses are non-small-cell lung cancer (NSCLC), 42% will present with localized disease and 58% will present with advanced disease. Scientific advances have led to improved 5-year survival rates. These advances are projected to improve, meaning that survivors of NSCLC will live longer. However, the extent of thoracic resection, radiation, chemotherapy, and immunotherapy treatment; common comorbid conditions like COPD (chronic obstructive pulmonary disease); and health behaviors exacerbate physical and emotional health burdens. Research has yet to address the management of physical deconditioning and unresolved symptoms (e.g., dyspnea, fatigue) in long-term survivors of lung cancer, both of which negatively impact health-related quality of life (HRQL). Self-management interventions that target lifestyle behaviors such as physical activity and stress reduction have demonstrated meaningful benefit in managing symptom burden. Additionally, scientific consensus supports the use of resistance training (RT) to mitigate functional decline from physical deconditioning by increasing muscular strength and endurance. However, frequently NSCLC survivors are sedentary or insufficiently active.
Lifestyle behaviors tend to cluster in families and social networks; thus, family members and friends of survivors are also at risk of poor health. An emerging consensus corroborates the inclusion of family and friends ("partners") of cancer survivors in self-management interventions. In this proposal, a partner is anyone the survivor considers a supportive person. Partners are critical sources of all types of social support across the cancer continuum. Importantly, partners must cope with their own concerns, including uncertainty surrounding the survivor's illness, fear of losing their partner, and the impact of their own health behaviors. Together, survivors and their partners may benefit significantly from a dyad-based lifestyle behavior intervention that supports physical and emotional health.
This research team has conducted extensive formative and preliminary research to develop a dyad-based intervention for NSCLC survivors and their partners. Early on, participants clearly indicated a preference for home-based, family- and safety-oriented interventions. Most recently, participants demonstrated the feasibility and preliminary effectiveness of a 12-week, dyad-based, telephone-delivered, self-management intervention known as Breathe Easier (BE), featuring mindfulness-based breathing exercises, meditation, and a walking program for dyads (N = 40; 20 dyads). Another study involved testing an RT program tailored to survivors only (n = 14). Feasibility and acceptability were strong and indicated positive improvements involving symptom burden and physical functioning.
Recognizing that evidence supports a multimodal approach, our research team aims to expand the BE intervention by integrating home-based RT via digital technology. The revised intervention will be known as BE+ and will include stage IV survivors to better understand the feasibility of this subgroup.
Theoretical Approach: The ORBIT model, which is a systematic framework for developing behavioral interventions, was used to develop a chain of evidence for the BE+ intervention program. BE+ is also built on the individual and family self-management theory (IFSMT), which proposes that successful change in health behavior self-management after a diagnosis of lung cancer requires active involvement by the survivor coupled with partner support. IFSMT encompasses three broad dimensions (context, process, outcomes) and promotes self-regulation, self-efficacy, and social support. The context dimension may impact individual and partner engagement in the self-management process and, therefore, the outcomes. Within the process dimension, self-regulation of the self-management of behaviors requires active involvement. Social support enhances the capacity to change and influences collaboration among dyads. The program components of BE+ enhance these three factors-leading to improved health behaviors. The behaviors of individuals in close, personal relationships are interdependent, and the actions of one person continuously affect the other's actions.
Design: A 12-week, non-randomized, one group pre-post feasibility study piloted among NSCLC survivors and their partners.
A purposive sample of 10 dyads (N = 20 participants) will be recruited from two cancer treatment centers in South Carolina. A partner, defined as a relative or close friend (i.e., spouse, sibling, adult child, neighbor), will be required for enrollment.
Analysis Plan: A power analysis will not be performed as this feasibility study does not warrant formal hypothesis testing, and all statistical tests will use an α cut point of 0.10 for meaningful preliminary differences. This nontraditional cut point (vs. α = 0.05) is more lenient due to the feasibility study design. Data analysis software will be used to obtain information regarding step count, and sleep SAS 9.4 (Cary, NC) software will be used to calculate means (± SD) and frequencies for demographic data. Normality will be checked using histogram and Q-Q plots combined with skewness and kurtosis statistics. When the outcome is normally distributed, independent t-tests will be performed to assess subset differences between survivors and partners to evaluate preliminary effects. Equal variances will be determined using the Folded F test, and thus the pooled version of the independent t-test will be used to determine preliminary meaningful differences. Then repeated measures ANOVA will be used to compare means among three time points. If normality is violated, the Mann-Whitney U Test will be used to compare outcome differences between survivors and partners, and Friedman's ANOVA by ranks will be used to evaluate the differences among three time points.
Exit interviews will be audio-recorded and professionally transcribed. The lead investigator will review transcripts and audio recordings to confirm accuracy. Thematic analysis will be used to analyze the transcripts following a six-phase approach: (1) become familiar with the data, (2) generate codes, (3) search for themes, (4) review themes, (5) define or name themes, (6) report findings and analysis.64 Transcripts will be iteratively analyzed by the research team to reach a consensus on codes, categories, and themes.
- Conditions
- Lung Cancer (Non-Small Cell), Self-management Behavior, Physical Activity, Stress, Quality of Life, Resistance Training
- Being tested
- Breathe Easier+
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Breathe Easier+Behavioural
Breathe Easier+ includes guided instruction using a digital manual, a walking program, RT training sessions, a weekly telephone coaching call, daily text messages, and assessments at three time points.
| Study group | Role | What they receive |
|---|---|---|
| Breathe Easier+ | Experimental | Breathe Easier+ includes guided instruction using a digital manual, a walking program, RT training sessions, a weekly telephone coaching call, daily text messages, and assessments at three time points. Receives: Behavioral: Breathe Easier+ |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the feasibility of the 12-week BE+ (BE with RT) among NSCLC survivors and their partners (dyads).
Feasibility will be evaluated on:
- Enrollment (25% of eligible participants),
- Retention (80% of participants at study completion),
- Adherence (80% to complete instruments at time points 1-3; Fitbit wear >5 days each week for 12 weeks),
- Participation (80% to log physical activity weekly, log breathing exercises weekly, set goals weekly, attend 2 resistance training sessions weekly, participate in weekly phone call, and read daily text messages),
Measured: 12 weeks
Secondary outcomes (6)
Explore preliminary effects of BE+ on increasing physical activity and overall fitness from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Physical activity and overall fitness will be measured:
7-Day Fitbit Step Count: 7-day total steps, measured during activity tracking, including active zone minutes and step counting for 24 hours/day, found to be accurate with an absolute percent error for steps of 1.5-9.6%.
Sit-to-Stand Test: Evaluates how long a person takes to rise from a chair and return to sitting in the chair, 5 times consecutively. Measured in seconds. A reliable and widely accepted measure of physical function. ICC = 0.937.
Step-in-Place Test: 2-minute marching in place, to estimate aerobic endurance; score is the number of times the right knee reaches the target, which has been validated with ICC = 0.90, correlation coefficient (r) = 0.69.
Arm Curl Test: 30 seconds of arm curls holding a weight to measure upper body strength and muscular endurance; ICC = 0.88.
Single Leg Stance: Length of time participant can stand on 1 leg with hands on hips to limit movement of arms; ICC = 0.87-0.97.
Measured: 12 weeks
Explore preliminary effects of BE+ for reduction in dyspnea from baseline to post-intervention among NSCLC survivors and their partners (dyads).
mMRC Dyspnea Scale: 1 item correlates with a self-report of breathlessness. Sensitivity (0.21-0.68), specificity (0.91-1.0).
Measured: 12 weeks
Explore preliminary effects of BE+ for reduction in stress response from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Fitbit Heart Rate Variability (HRV): Measure of the fluctuation of the length of heartbeat intervals, representing the ability of the heart to respond to varying physiological stimuli, signifying stress response. ICC = 0.6
Measured: 12 weeks
Explore preliminary effects of BE+ for improvement in sleep from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Fitbit Sleep: Objective measure of sleep quantity based on combined body movement and HRV algorithm. Sleep measures captured by Fitbit include total minutes asleep, minutes awake, minutes to fall asleep, minutes awake after sleep, total time in bed, and sleep stages. Sensitivity = .95; specificity = 0.58-0.69.
Pittsburgh Sleep Quality Index (PSQI): 19 items measuring sleep quality, sleep latency, sleep efficiency, sleep duration, sleep disturbances, use of sleep medications, and daytime dysfunction.55 Cronbach's alpha (α) = 0.77-0.83; r = 0.77-0.85.
Measured: 12 weeks
Explore preliminary effects of BE+ for reduction in fatigue from baseline to post-intervention among NSCLC survivors and their partners (dyads).
FACIT Fatigue Scale v.4: 13 items measuring fatigue during usual activity over the past 7 days. α = 0.96; ICC = 0.95.
Measured: 12 weeks
Explore preliminary effects of BE+ for improvement in health-related quality of life (HRQL) from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Short Form Health Survey (SF-36): 36 items evaluating HRQL through physical function, social functioning, physical role limitations, emotional role limitations, emotional health, vitality, pain, and general health perception. α = 0.78-0.93.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2025
- Study start15 Aug 2025
- Primary completionMay 2026 (estimated)
- Study completionMay 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (27)Papers the sponsor has linked to this study.
- Other trials for Lung Cancer (Non-Small Cell)Studies of the same condition, open and under way.
- More trials run by University of South CarolinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of South Carolina
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amanda Dyer, University of South Carolina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07214441
- Sponsor's protocol ID
- Pro00144866
- Status last verified
- Oct 2025
- First submitted
- 12 Sep 2025
- Last updated
- 9 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: On request
Publications
Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials: should significance thresholds be reconsidered? BMC Med Res Methodol. 2014 Mar 20;14:41. doi: 10.1186/1471-2288-14-41.
PubMed 24650044Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage. 2004 Feb;27(2):140-8. doi: 10.1016/j.jpainsymman.2003.12.002.
PubMed 15157038Dorn LD, Lucke JF, Loucks TL, Berga SL. Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann Clin Biochem. 2007 May;44(Pt 3):281-4. doi: 10.1258/000456307780480954.
PubMed 17456296Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and Heart Rate Variability: A Meta-Analysis and Review of the Literature. Psychiatry Investig. 2018 Mar;15(3):235-245. doi: 10.30773/pi.2017.08.17. Epub 2018 Feb 28.
PubMed 29486547Tsiligianni IG, Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Schultz K, Kollen BJ, van der Molen T, Kocks JW. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis. 2016 May 18;11:1045-52. doi: 10.2147/COPD.S99793. eCollection 2016.
PubMed 27274226Ponce-Gonzalez JG, Sanchis-Moysi J, Gonzalez-Henriquez JJ, Arteaga-Ortiz R, Calbet JA, Dorado C. A reliable unipedal stance test for the assessment of balance using a force platform. J Sports Med Phys Fitness. 2014 Feb;54(1):108-17.
PubMed 24445552Melo TA, Duarte ACM, Bezerra TS, Franca F, Soares NS, Brito D. The Five Times Sit-to-Stand Test: safety and reliability with older intensive care unit patients at discharge. Rev Bras Ter Intensiva. 2019;31(1):27-33. doi: 10.5935/0103-507X.20190006. Epub 2019 Mar 14.
PubMed 30892478Chen MD, Kuo CC, Pellegrini CA, Hsu MJ. Accuracy of Wristband Activity Monitors during Ambulation and Activities. Med Sci Sports Exerc. 2016 Oct;48(10):1942-9. doi: 10.1249/MSS.0000000000000984.
PubMed 27183123Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess. 1990 Winter;55(3-4):610-7. doi: 10.1080/00223891.1990.9674095.
PubMed 2280326Kim M, Yeom HE, Jung MS. Validation and psychometric properties of the multidimensional scale of perceived social support among Korean breast cancer survivors. Asia Pac J Oncol Nurs. 2022 Jan 30;9(4):229-235. doi: 10.1016/j.apjon.2022.01.004. eCollection 2022 Apr.
PubMed 35571625McDonnell KK, Gallerani DG, Newsome BR, Owens OL, Beer J, Myren-Bennett AR, Regan E, Hardin JW, Webb LA. A Prospective Pilot Study Evaluating Feasibility and Preliminary Effects of Breathe Easier: A Mindfulness-based Intervention for Survivors of Lung Cancer and Their Family Members (Dyads). Integr Cancer Ther. 2020 Jan-Dec;19:1534735420969829. doi: 10.1177/1534735420969829.
PubMed 33118443Cooley ME, Blonquist TM, Hong F, Nayak MM, Crouter SE, Hayman LL, Jaklitsch MT, Emmons KM, Bueno R. The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomes. Psychooncology. 2019 Apr;28(4):920-923. doi: 10.1002/pon.5002. Epub 2019 Feb 12. No abstract available.
PubMed 30673155Blok AC, Blonquist TM, Nayak MM, Somayaji D, Crouter SE, Hayman LL, Colson YL, Bueno R, Emmons KM, Cooley ME. Feasibility and acceptability of "healthy directions" a lifestyle intervention for adults with lung cancer. Psychooncology. 2018 Jan;27(1):250-257. doi: 10.1002/pon.4443. Epub 2017 May 31.
PubMed 28426922Heredia-Ciuro A, Martin-Nunez J, Lopez-Lopez JA, Lopez-Lopez L, Granados-Santiago M, Calvache-Mateo A, Valenza MC. Effectiveness of healthy lifestyle-based interventions in lung cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2022 Dec 21;31(1):71. doi: 10.1007/s00520-022-07542-0.
PubMed 36542189Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
PubMed 31626055
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating the Feasibility and Preliminary Effects of a Remotely Delivered Dyad-Based Intervention Incorporating Resistance Training to Improve Fitness in Individuals With Non-Small-Cell Lung Cancer and in Their Partners
- ClinicalTrials.gov ID
- NCT07214441
- Acronym / sponsor ID
- Pro00144866
- Conditions
- Lung Cancer (Non-Small Cell), Self-management Behavior, Physical Activity, Stress, Quality of Life, Resistance Training
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of South CarolinaUniversity, hospital or other
- Study start
- 15 Aug 2025 (actual)
- Primary completion
- May 2026 (estimated)
- Study completion
- May 2026 (estimated)
- First posted
- 9 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This non-randomized, single group study will test a 12-week, behavioral intervention for physical activity and stress management for survivors of non-small cell lung cancer (NSCLC) and a partner (family member or friend). The goals of this intervention, Breathe Easier+ (BE+), are to increase overall physical activity and overall fitness and to reduce symptoms (fatigue, breathlessness, sleep, and stress).
The aim of this study is to evaluate the enrollment, retention, adherence, participation, and acceptability of the 12-week BE+ among NSCLC survivors and their partners. The study also aims to:
- Explore preliminary intervention effects of BE+ on increasing physical activity and overall fitness (measured by 7-day Fitbit wear, step-in-place test, chair sit-and-stand, arm curl test, and balance test) from baseline to post-intervention among NSCLC survivors and their partners.
- Explore preliminary effects of BE+ for improvement in stress response, symptom burden (fatigue, dyspnea), sleep, and HRQL from baseline to post-intervention among NSCLC survivors and their partners.
Participants will receive education, social support, coaching, a guided walking program, supervised resistance training (RT), and meditations delivered via digital technology (tablet, smartphone, and Fitbit).
Detailed description
Lung cancer is the second-most diagnosed malignancy, accounting for more annual deaths than breast, prostate, and colorectal cancers combined. Approximately 80% of lung cancer diagnoses are non-small-cell lung cancer (NSCLC), 42% will present with localized disease and 58% will present with advanced disease. Scientific advances have led to improved 5-year survival rates. These advances are projected to improve, meaning that survivors of NSCLC will live longer. However, the extent of thoracic resection, radiation, chemotherapy, and immunotherapy treatment; common comorbid conditions like COPD (chronic obstructive pulmonary disease); and health behaviors exacerbate physical and emotional health burdens. Research has yet to address the management of physical deconditioning and unresolved symptoms (e.g., dyspnea, fatigue) in long-term survivors of lung cancer, both of which negatively impact health-related quality of life (HRQL). Self-management interventions that target lifestyle behaviors such as physical activity and stress reduction have demonstrated meaningful benefit in managing symptom burden. Additionally, scientific consensus supports the use of resistance training (RT) to mitigate functional decline from physical deconditioning by increasing muscular strength and endurance. However, frequently NSCLC survivors are sedentary or insufficiently active.
Lifestyle behaviors tend to cluster in families and social networks; thus, family members and friends of survivors are also at risk of poor health. An emerging consensus corroborates the inclusion of family and friends ("partners") of cancer survivors in self-management interventions. In this proposal, a partner is anyone the survivor considers a supportive person. Partners are critical sources of all types of social support across the cancer continuum. Importantly, partners must cope with their own concerns, including uncertainty surrounding the survivor's illness, fear of losing their partner, and the impact of their own health behaviors. Together, survivors and their partners may benefit significantly from a dyad-based lifestyle behavior intervention that supports physical and emotional health.
This research team has conducted extensive formative and preliminary research to develop a dyad-based intervention for NSCLC survivors and their partners. Early on, participants clearly indicated a preference for home-based, family- and safety-oriented interventions. Most recently, participants demonstrated the feasibility and preliminary effectiveness of a 12-week, dyad-based, telephone-delivered, self-management intervention known as Breathe Easier (BE), featuring mindfulness-based breathing exercises, meditation, and a walking program for dyads (N = 40; 20 dyads). Another study involved testing an RT program tailored to survivors only (n = 14). Feasibility and acceptability were strong and indicated positive improvements involving symptom burden and physical functioning.
Recognizing that evidence supports a multimodal approach, our research team aims to expand the BE intervention by integrating home-based RT via digital technology. The revised intervention will be known as BE+ and will include stage IV survivors to better understand the feasibility of this subgroup.
Theoretical Approach: The ORBIT model, which is a systematic framework for developing behavioral interventions, was used to develop a chain of evidence for the BE+ intervention program. BE+ is also built on the individual and family self-management theory (IFSMT), which proposes that successful change in health behavior self-management after a diagnosis of lung cancer requires active involvement by the survivor coupled with partner support. IFSMT encompasses three broad dimensions (context, process, outcomes) and promotes self-regulation, self-efficacy, and social support. The context dimension may impact individual and partner engagement in the self-management process and, therefore, the outcomes. Within the process dimension, self-regulation of the self-management of behaviors requires active involvement. Social support enhances the capacity to change and influences collaboration among dyads. The program components of BE+ enhance these three factors-leading to improved health behaviors. The behaviors of individuals in close, personal relationships are interdependent, and the actions of one person continuously affect the other's actions.
Design: A 12-week, non-randomized, one group pre-post feasibility study piloted among NSCLC survivors and their partners.
A purposive sample of 10 dyads (N = 20 participants) will be recruited from two cancer treatment centers in South Carolina. A partner, defined as a relative or close friend (i.e., spouse, sibling, adult child, neighbor), will be required for enrollment.
Analysis Plan: A power analysis will not be performed as this feasibility study does not warrant formal hypothesis testing, and all statistical tests will use an α cut point of 0.10 for meaningful preliminary differences. This nontraditional cut point (vs. α = 0.05) is more lenient due to the feasibility study design. Data analysis software will be used to obtain information regarding step count, and sleep SAS 9.4 (Cary, NC) software will be used to calculate means (± SD) and frequencies for demographic data. Normality will be checked using histogram and Q-Q plots combined with skewness and kurtosis statistics. When the outcome is normally distributed, independent t-tests will be performed to assess subset differences between survivors and partners to evaluate preliminary effects. Equal variances will be determined using the Folded F test, and thus the pooled version of the independent t-test will be used to determine preliminary meaningful differences. Then repeated measures ANOVA will be used to compare means among three time points. If normality is violated, the Mann-Whitney U Test will be used to compare outcome differences between survivors and partners, and Friedman's ANOVA by ranks will be used to evaluate the differences among three time points.
Exit interviews will be audio-recorded and professionally transcribed. The lead investigator will review transcripts and audio recordings to confirm accuracy. Thematic analysis will be used to analyze the transcripts following a six-phase approach: (1) become familiar with the data, (2) generate codes, (3) search for themes, (4) review themes, (5) define or name themes, (6) report findings and analysis.64 Transcripts will be iteratively analyzed by the research team to reach a consensus on codes, categories, and themes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Breathe Easier+ | Experimental | Behavioral: Breathe Easier+Breathe Easier+ includes guided instruction using a digital manual, a walking program, RT training sessions, a weekly telephone coaching call, daily text messages, and assessments at three time points. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Survivors of NSCLC who have completed definitive treatment within the last 2 years.
- All participants must have a health clearance for physical activity signed by a healthcare provider; have Wi-Fi access; be able to provide informed consent; and be able to speak and read English.
Key exclusion criteria (2 listed)
- Survivors on current definitive treatment.
- All participants with a history of recurrent falls; a substantial mobility impairment related to chronic disease or injury; and lack of physical activity readiness as determined by a healthcare provider.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Breathe Easier+Breathe Easier+ includes guided instruction using a digital manual, a walking program, RT training sessions, a weekly telephone coaching call, daily text messages, and assessments at three time points. | Behavioural | Breathe Easier+ |
Primary outcome
Evaluate the feasibility of the 12-week BE+ (BE with RT) among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Feasibility will be evaluated on: 1. Enrollment (25% of eligible participants), 2. Retention (80% of participants at study completion), 3. Adherence (80% to complete instruments at time points 1-3; Fitbit wear >5 days each week for 12 weeks), 4. Participation (80% to log physical activity weekly, log breathing exercises weekly, set goals weekly, attend 2 resistance training sessions weekly, participate in weekly phone call, and read daily text messages),
6 secondary outcomes
Explore preliminary effects of BE+ on increasing physical activity and overall fitness from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Explore preliminary effects of BE+ for reduction in dyspnea from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Explore preliminary effects of BE+ for reduction in stress response from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Explore preliminary effects of BE+ for improvement in sleep from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Explore preliminary effects of BE+ for reduction in fatigue from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Explore preliminary effects of BE+ for improvement in health-related quality of life (HRQL) from baseline to post-intervention among NSCLC survivors and their partners (dyads).
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2025.
- Background: PubMed 24650044Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials: should significance thresholds be reconsidered? BMC Med Res Methodol. 2014 Mar 20;14:41. doi: 10.1186/1471-2288-14-41.
- Background: PubMed 15157038Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage. 2004 Feb;27(2):140-8. doi: 10.1016/j.jpainsymman.2003.12.002.
- Background: PubMed 17456296Dorn LD, Lucke JF, Loucks TL, Berga SL. Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Ann Clin Biochem. 2007 May;44(Pt 3):281-4. doi: 10.1258/000456307780480954.
- Background: PubMed 29486547Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and Heart Rate Variability: A Meta-Analysis and Review of the Literature. Psychiatry Investig. 2018 Mar;15(3):235-245. doi: 10.30773/pi.2017.08.17. Epub 2018 Feb 28.
- Background: PubMed 27274226Tsiligianni IG, Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Schultz K, Kollen BJ, van der Molen T, Kocks JW. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis. 2016 May 18;11:1045-52. doi: 10.2147/COPD.S99793. eCollection 2016.
- Background: PubMed 24445552Ponce-Gonzalez JG, Sanchis-Moysi J, Gonzalez-Henriquez JJ, Arteaga-Ortiz R, Calbet JA, Dorado C. A reliable unipedal stance test for the assessment of balance using a force platform. J Sports Med Phys Fitness. 2014 Feb;54(1):108-17.
- Background: PubMed 30892478Melo TA, Duarte ACM, Bezerra TS, Franca F, Soares NS, Brito D. The Five Times Sit-to-Stand Test: safety and reliability with older intensive care unit patients at discharge. Rev Bras Ter Intensiva. 2019;31(1):27-33. doi: 10.5935/0103-507X.20190006. Epub 2019 Mar 14.
- Background: PubMed 27183123Chen MD, Kuo CC, Pellegrini CA, Hsu MJ. Accuracy of Wristband Activity Monitors during Ambulation and Activities. Med Sci Sports Exerc. 2016 Oct;48(10):1942-9. doi: 10.1249/MSS.0000000000000984.
- Background: PubMed 2280326Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess. 1990 Winter;55(3-4):610-7. doi: 10.1080/00223891.1990.9674095.
- Background: PubMed 35571625Kim M, Yeom HE, Jung MS. Validation and psychometric properties of the multidimensional scale of perceived social support among Korean breast cancer survivors. Asia Pac J Oncol Nurs. 2022 Jan 30;9(4):229-235. doi: 10.1016/j.apjon.2022.01.004. eCollection 2022 Apr.
- Background: PubMed 33118443McDonnell KK, Gallerani DG, Newsome BR, Owens OL, Beer J, Myren-Bennett AR, Regan E, Hardin JW, Webb LA. A Prospective Pilot Study Evaluating Feasibility and Preliminary Effects of Breathe Easier: A Mindfulness-based Intervention for Survivors of Lung Cancer and Their Family Members (Dyads). Integr Cancer Ther. 2020 Jan-Dec;19:1534735420969829. doi: 10.1177/1534735420969829.
- Background: PubMed 30673155Cooley ME, Blonquist TM, Hong F, Nayak MM, Crouter SE, Hayman LL, Jaklitsch MT, Emmons KM, Bueno R. The effect of a lifestyle risk reduction intervention on lifestyle adherence and health-related quality of life in nonsmall cell lung cancer survivors: Feasibility study outcomes. Psychooncology. 2019 Apr;28(4):920-923. doi: 10.1002/pon.5002. Epub 2019 Feb 12. No abstract available.
- American Cancer Society. (2025). Cancer facts and figures 2025.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. On request
Related trials for Lung Cancer (Non-Small Cell)
RecruitingPhase 3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
RecruitingPhase 3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Non-small Cell Lung Cancer
Not yet recruitingPhase 1
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
RecruitingPhase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Breathe Easier+ in people with Lung Cancer (Non-Small Cell) and Self-management Behavior, run by University of South Carolina at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 9 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the feasibility of the 12-week BE+ (BE with RT) among NSCLC survivors and their partners (dyads). (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07214441, which also lists 27 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2025.